Obiettivo The aim of this project is to select peptide epitopes that mimic neutralization sensitive domains of HIV-1 envelope and may function as candidate HIV-1 vaccines. To date, efforts to develop a truly prophylactic HIV-1 vaccine have been hindered by difficult y in identifying immunogens that elicit broadly neutralizing antibodies. This lack of significant cross-protection raises further concerns on the capacity of classical Env-based vaccines to afford substantial protection against field isolates. Indeed, curr ent unmodified gp120 or gp140 envelope-based vaccines in human subjects have shown little or no protection from heterologous HIV-1 isolates such as would be encountered in the field. This indicates that vaccine trials with currently available immunogens wi ll afford low percentages of protection with a large number of vaccine breakthroughs and will raise ethical and financial issues concerning the treatment of any volunteers who become infected. It is of the highest priority that a focused effort is undertak en to develop novel Env antigens capable of inducing broad and potent neutralising antibodies to a wide variety of strains. Consistently, this consortium is developing a new generation of Env antigens based on complex but conserved epitopes to induce broad neutralising antibodies. This objective will be achieved by two complementary strategies: a. Screening of Random Peptide Libraries with novel MAbs that neutralise primary HIV-1 isolates assigned to distinct clades; b. designing of 30-40 amino acid peptide s that mimic discontinuous regions of gp120 and gp41 that are sensitive to neutralization by antibodies and are conserved among HIV strains of distinct clades. These include the CD4-binding domain, the bridging sheet and the pre-fusogenic harpin loop of gp 41. In this two years proposal the novel vaccine candidates will be validated in mice; however, the Consortium is endowed with the facilities and resources to proceed to monkeys models of HIV-1 infection. Campo scientifico natural sciencesbiological scienceszoologymammalogyprimatologymedical and health sciencesbasic medicineimmunologymedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesnatural scienceschemical sciencesorganic chemistryamines Parole chiave HIV Multiple Antigenic Peptides Random Peptide Libraries envelope antigens Programma(i) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Argomento(i) LSH-2003-2.3.0-1 - Highly innovative approaches for the development of new interventions for HIV, malaria and tuberculosis Invito a presentare proposte FP6-2003-LIFESCIHEALTH-3 Vedi altri progetti per questo bando Meccanismo di finanziamento STREP - Specific Targeted Research Project Coordinatore UNIVERSITÀ DI NAPOLI FEDERICO II- DIPARTIMENTO DI BIOCHIMICA E BIOTECNOLOGIE MEDICHE Contributo UE Nessun dato Indirizzo Via S. Pansini 5 NAPOLI Italia Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato Partecipanti (3) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE Paesi Bassi Contributo UE Nessun dato Indirizzo Lange Kleiweg 139 RIJSWIJK Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH Austria Contributo UE Nessun dato Indirizzo Nussdorfer Laende 11 VIENNA Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato UNIVERSITY OF APPLIED LIFE SCIENCES AND NATURAL RESOURCES Austria Contributo UE Nessun dato Indirizzo Muthgasse 18B VIENNA Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato
